PTPRC and cancer: Indeed, the MDA231–Luc tumours from cixutumumab-treated mice exhibited significantly increased levels of VEGFR+ vascular endothelial (VE) cells, CD45+ leukocytes, F4/80+ or Iba-1+ macrophages and FSP-1+ cancer-associated fibroblasts (Fig. 3a).